Call for Abstract
Abstract Submission Period
Abstract submission is open from October 2, 2024.
Abstract submission deadline:
5:00pm, December 19 (Thursday), 2024 (Japan Standard Time, UTC+9)
Abstract submission deadline:
5:00pm, December 19 (Thursday), 2024 (Japan Standard Time, UTC+9)
Application for Abstract
FujiRetina 2025 is accepting poster presentation only (there will be no e-poster this time).
All presenters are requested to come to the venue and affix their posters by themselves.
Select an appropriate category from the following list.
All presenters are requested to come to the venue and affix their posters by themselves.
Select an appropriate category from the following list.
Category
| 01 | Basic medicine | 09 | Central serous chorioretinopathy |
|---|---|---|---|
| 02 | Diagnosis/Examination | 10 | Age-related macular degeneration |
| 03 | Retinal detachment | 11 | Retinal dystrophies |
| 04 | Diabetic retinopathy | 12 | Surgery |
| 05 | Retinal vein occlusion | 13 | Treatments other than surgery |
| 06 | Pathologic myopia | 14 | Low vision |
| 07 | Macular hole/Epiretinal membrane | 15 | Other categories |
| 08 | Macular edema |
Submission Guidelines
- All abstracts must be submitted in English exclusively via the online abstract submission system. Submissions by post, email, fax or any other means will NOT be accepted.
- AUTHORS – FIRST (PRESENTING) AUTHOR – The first author will be the presenting author. The first (presenting) author is expected to register and pay the full registration fee, prepare the presentation and attend the conference.
- Please provide an accurate email address of the first (presenting) author. Abstract submission results and abstract-related correspondence will be sent by email to the first author.
- The first author cannot be the first author of another abstract.
- CO-AUTHOR(S) – A maximum of 12 co-authors are allowed for each abstract. Type in the names and affiliations as you would like them to appear in published material.
- The ABSTRACT TITLE should be no longer than 100 characters including spaces.
- Abstract Content (excluding title, authors, affiliations) should include the following headings: PURPOSE, METHODS, RESULTS and CONCLUSIONS. The abstract must not exceed 250 words. Do not include graphs, tables, images and references in the abstract.
- Declaration of conflicts of interest is mandatory for all authors (See below for details).
- In the abstract submission system, please select whether you have obtained approval from the ethics committee, e.g. IRB, or if it was not necessary. This does not need to be stated in the abstract text.
- Regarding approval ethics committee approval for animal research, e.g. IACUC, please select whether you have obtained approval of the committee, or if it was not necessary, on the abstract submission form. The author is not required to mention it in the abstract body.
- In the abstract submission system, please select whether you obtained informed consent, or if it was not necessary. This does not need to be stated in the abstract text.
- Successfully submitted abstracts will be acknowledged with an email including an abstract number. If you do not receive an email within 24 hours after submission, please contact the Congress Secretariat by email at fujiretina@jtbcom.co.jp.
- Late submissions will NOT be considered.
- Authors will be notified of acceptance or rejection in middle of February 2025.
Travel Grant
FujiRetina encourages non-Japanese overseas ophthalmologists to submit abstracts. A number of abstracts will be selected as travel grant recipients by the Organizing Committee. 1,000 USD will be awarded to the first author of the submitted abstract. When selecting an appropriate category, please also select the travel grant application at the same time.
Note
- The travel grants will be presented to the grant winners after their abstract presentations at the meeting. All travel grant recipients must be at FujiRetina in person.
- Travel grant recipients are responsible for making their own arrangements for transportation to the venue and accommodations during the meeting period.FujiRetina will not provide any stipends or reimbursements beyond the 1,000 USD.
- Results of the awards will be announced by email in February 2025.
- Practicing physicians and trainees are all eligible for the travel grants.
Best Poster Awards
These awards are given to the three best posters presented at the meeting.
Poster winners will be recognized publicly at the Reception on March 29th, 2025.
Poster winners will be recognized publicly at the Reception on March 29th, 2025.
Conflict of Interest
Authors have to report any conflict of interest at the beginning of any presentation at FujiRetina. If the presentation is accepted, the category of conflict of interest and company names must be disclosed in the poster for presentation based on “the rules for conflict of interest of Japanese Ophthalmological Society."
A. Presentations to Which These Rules are Applicable
These rules are applicable to all presentations, including those in Co-Sponsored Seminars, Free Paper, Panel Discussion, Poster presentation, etc.B. Report on Conflict of Interest at Abstract Submission
Report the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation. If conflict of interest is “present," enter the category, class and company names after each author's name in the entry field of “Conflict of Interest" on the abstract submission form. If conflict of interest is absent, enter “category N." Confirm the declaration is correct prior to the registration. Categories and classes are as follows.1. Categories
F (Financial Support):
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
I (Personal Financial Interest):
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
E (Employee):
In the case where the author is an employee of an interested company.
In the case where the author is an employee of an interested company.
C (Consultant):
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
P (Patent):
In the case where the author holds a patent or is in the process of applying for a patent.
In the case where the author holds a patent or is in the process of applying for a patent.
R:
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
2. Class
Ⅰ．0 yen
Ⅱ．From 1 to less than 500,000 yen
Ⅲ．From 500,000 to 5,000,000 yen
Ⅳ．Over 5,000,000 yen
*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
Ⅱ．From 1 to less than 500,000 yen
Ⅲ．From 500,000 to 5,000,000 yen
Ⅳ．Over 5,000,000 yen
*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
C. Disclosures in the Abstract and Slide Decks
Abstract:
The presence or absence of conflict of interest to be disclosed for the author (including co-authors) will be automatically shown at the end of the abstract, according to “the detailed rules of the standard for disclosure in the Japanese Ophthalmological Society." For categories F, C and R, only class IV (over 5,000,000 yen) will be correspond to “presence".
Slide and Poster:
If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide and at the end of the poster. For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed.
* In the case of "Category P" (the author holds a patent or is in the process of applying for a patent), the company name need not to described.
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
Privacy policy
"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes. The registration process for applications has been commissioned to c/o JTB Communication Design, Inc. in order to facilitate management operations.
Inquiries
Secretariat of FujiRetinac/o JTB Communication Design, Inc.,
JTB Bldg. 8F, 2-1-25 Kyutaromachi, Chuo-ku, Osaka 541-0056, Japan
E-mail: fujiretina@jtbcom.co.jp